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Abstract
Background: Deficiencies of iron and folic acid during pregnancy can lead to adverse outcomes
for the fetus, thus supplements are recommended. Adherence to current tablet-based supplements
is documented to be poor. Recently a powdered form of micronutrients has been developed which
may decrease side-effects and thus improve adherence. However, before testing the efficacy of the
supplement as an alternate choice for supplementation during pregnancy, the bioavailability of the
iron needs to be determined. Our objective was to measure the relative bioavailability of iron and
folic acid from a powdered supplement that can be sprinkled on semi-solid foods or beverages
versus a traditional tablet supplement in pregnant women.
Methods: Eighteen healthy pregnant women (24 – 32 weeks gestation) were randomized to
receive the supplements in a crossover design. Following ingestion of each supplement, the changes
(over baseline) in serum iron and folate over 8 hours were determined. The powdered supplement
contained 30 mg of iron as micronized dispersible ferric pyrophosphate with an emulsifier coating
and 600 μg folic acid; the tablet contained 27 mg iron from ferrous fumarate and 1000 μg folic acid.
Results: Overall absorption of iron from the powdered supplement was significantly lower than
the tablet (p = 0.003). There was no difference in the overall absorption of folic acid between
supplements. Based on the differences in the area under the curve and doses, the relative
bioavailability of iron from powdered supplement was lower than from the tablet (0.22).
Conclusion: The unexpected lower bioavailability of iron from the powdered supplement is
contrary to previously published reports. However, since pills and capsules are known to be poorly
accepted by some women during pregnancy, it is reasonable to continue to explore alternative
micronutrient delivery systems and forms of iron for this purpose.
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Background
Iron deficiency anemia (IDA) is the most common micro-
nutrient deficiency in women of reproductive age affect-
ing approximately 17% of women during pregnancy [1].
Supplements containing iron and folic acid are recom-
mended during pregnancy by various health organiza-
tions to meet requirements and to reduce the risk for
deficiency [2]. Folate deficiency has significantly
decreased in North America primarily due to folic acid for-
tification of the food supply but the need for adequate
folate intake prior to conception and during the early
weeks of pregnancy remains a significant concern to
reduce the risk for the development of neural tube defects
(NTD) [3]. Approximately 57.7% of Canadian women
will take a multivitamin preparation prior to conception
and up to 89.7% will take multivitamins containing folic
acid during pregnancy, primarily in the first three months
of gestation. [4]. Up to half of the women taking multivi-
tamin and iron supplements during pregnancy will expe-
rience some gastrointestinal side effects, particularly
constipation and nausea [5-7], thus it is not surprising
that adherence to supplementation during pregnancy is
only about 50% [7]. This limited adherence to supple-
mentation during pregnancy due to gastrointestinal side
effects associated with supplemental iron can be further
exacerbated by morning sickness and may also be related
to tablet size [7-9].
A recent innovation in the delivery of minerals and vita-
mins has been a powdered form of iron and folic acid
packaged in single-serve sachets that are sprinkled over
any semi-solid foods just before consumption. The inno-
vation has been coined 'point of use' or 'home'-fortifica-
tion. 'Point of use' fortification was designed to improve
adherence by reducing the side-effects of the iron through
the use of microencapsulated ferrous fumarate as the iron
source, as well as the buffering effect of the food to which
the fortificant is added. The encapsulate is an edible vege-
table- based lipid which dissolves in the low pH environ-
ment of the stomach. Microencapsulation masks the
metallic taste of the iron and possibly protects the gastric
epithelium from local irritation by the iron salt[10].
'Point of use' fortification has been associated with a
reduction in the incidence of anemia and is associated
with improved adherence when provided to infants and
children [11-14].
A disadvantage of using microencapsulated ferrous fuma-
rate as the iron source in 'point of use' fortificants is that
it has limited solubility (because of the lipid encapsulate)
thus it is not readily suitable for use in beverages. To
potentially improve adherence it would be of value to use
a mixture of minerals and vitamins (including iron) that
would readily disperse in liquids or semi-solids. A new
compound SunActive Fe® is a micronized dispersible form
of ferric pyrophosphate (MDFP) with an emulsifier coat-
ing, which was designed to increase the bioavailability
and solubility of ferric pyrophosphate. While ferric pyro-
phosphate has excellent organoleptic properties, the bio-
availability is quite low compared to ferrous fumarate
[15] The potential advantage of MDFP is that it dissolves
readily in liquids or semi-liquid foods and is reported to
have a relative bioavailability (RBV) of 82 – 92% depend-
ing on the food-based carrier [16].
There is no data on the absorption kinetics of MDFP and
powdered folic acid when used in a multi-vitamin/min-
eral supplement in pregnant women. Thus, the objective
of the current study was to evaluate the relative bioavaila-
bility and absorption kinetics for both iron and folic acid
using the new 'point of use' fortificant containing 600 μg
of folic acid and MDFP (SunActive Fe®) to supply 30 mg
of iron, compared to a traditional pregnancy tablet sup-
plement, which contains 1000 μg of folic acid and 27 mg
of iron from ferrous fumarate.
Methods
Subjects
Twenty-six healthy women (aged 18 to 45 y) between 24
to 32 weeks gestation were recruited from staff and visi-
tors at the Hospital for Sick Children, Toronto between
December 2005 and June 2006. Eight subjects withdrew
from the study due to pregnancy complications or time
conflicts, thus 18 subjects were enrolled. Women were
excluded if they had any of the following: significant com-
plications of pregnancy; acute or chronic illness or dis-
eases; any hematological disorders; any conditions that
would interfere with the absorption, metabolism or excre-
tion of iron or folic acid; on antibiotic therapy; known or
suspected allergies to supplement ingredients; anemia
(Hb<110 g/L) or elevated hemoglobin (= 144 g/L) or a
blood transfusion 3 months prior to enrollment. Prior
multivitamin/mineral supplement use did not preclude
participation in the study. One subject with hemoglobin
concentration of 106 g/L was inadvertently included into
the study. However, the serum iron and folate results from
this subject did not affect the study outcomes.
At baseline the mean (± SD) age of the subjects was 33 ±
4 years; gestational age 26.4 ± 2.8 weeks. None were
smokers, one was a vegetarian and the majority (56%)
had one child. All had single-birth pregnancies. At the
time of recruitment, sixteen out of the eighteen women
were taking daily supplements containing 27 mg iron and
1000 μg folic acid.
Clinical trial application approval was obtained from
Health Canada and the study protocol was approved the
Research Ethics Board of the Hospital for Sick ChildrenBMC Pregnancy and Childbirth 2009, 9:33 http://www.biomedcentral.com/1471-2393/9/33
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and the University of Toronto. Consent from each subject
was obtained on the first study visit and all data was coded
to ensure confidentiality.
Study Design and Methods
This was a randomized, 3-period, 2-intervention crosso-
ver study. (Figure 1). Composition of the two supple-
ments, are shown in Table 1. The powdered supplement
was prepared using SunActive Fe® and other micronutri-
ents by Nealanders International Inc. (Mississauga Can-
ada) and repackaged into 1 gram aliquots in white plastic
Tamper Seal Vials (Pharmasystems). SunActive Fe ® is a
proprietary iron source produced by Taiyo Kagaku Ltd
(Yokkaichi Japan). The control supplement, Materna® is
manufactured by Wyeth Consumer Healthcare Inc (Mis-
sissauga Canada). The form of iron in the traditional tab-
let supplement is ferrous fumarate.
Subjects attended a baseline and two subsequent assess-
ment visits, each one week apart. Prior to each assessment,
subjects fasted overnight (for 10 hours) and refrained
from taking their usual supplements. Subjects were
allowed to take their usual supplements between each
assessment visit. During each assessment an indwelling
intravenous catheter was inserted and six venous blood
samples (5 ml each) were drawn at 0, 1, 2, 3, 4 and 8
hours after supplement ingestion. Blood samples were
collected without and with the anticoagulant EDTA for
latter determination of iron and folate biochemical indi-
ces, respectively. The tubes for folate analysis were covered
with foil to block light. Serum and plasma were separated
from whole blood by centrifugation (1500 RPM for 15
min at 4°C). One percent sodium ascorbate was added to
stabilize the folate. Samples were aliquoted and frozen at
-80°C until analysis.
All subjects participated in an initial assessment during
which neither the tablet nor the powdered supplement
were provided. During the initial assessment, hematolog-
ical status was determined as well as serum iron diurnal
variation by determining serum iron concentrations over
the 8-hour assessment period (as described above). Since
there is no discernable diurnal variation for folate, plasma
folate was not measured during the initial assessment
[17]. For the second and third assessment periods, the
subjects were randomly assigned (by drawing coloured
poker chips from a bag) to either the tablet supplement or
the powdered supplement which the subjects were
allowed to sprinkle either onto a semi-solid food such as
applesauce or a liquid such as juice prior to consumption.
If the tablet supplement was ingested during the second
assessment period, then the powdered supplement would
be provided during the third assessment period and vice
versa. Supplements were taken with a standardized morn-
Table 1: Supplement composition
Materna®
per 1 tablet
Powdered Supplement
per 1 g dose
Vitamin A, μg RE 1500 800
Vitamin C, mg 100 70
Vitamin D, μg 6.4 5
Vitamin E, mg a-TE 30 15
Vitamin B1, Thiamin mg 3 1.4
Vitamin B2, Riboflavin mg 3.4 1.4
Vitamin B6, Niacin mg 10 1.9
Vitamin B12, μg1 2 2 . 6
Folic Acid, μg 1000 600
Niacin, mg NE 20 18
Iron, mg 1 27 30
Zinc mg 25 5.5
Copper, mg 2 1
Iodine, μg1 5 0 2 2 0
Beta-Carotene, unit 1500 0
Biotin, μg3 0 3 0
Calcium (Calcium Carbonate), mg 250 0
Chromium (Chromic Cloride), μg2 5 0
D-Pantothenic Acid, mg 10 6
Magnesium (Magnesium oxide), mg 50 0
Manganese (Manganese Sulphate), mg 5 0
Molybdenum (Sodium Molybdate), μg2 5 0
Selenium (Sodium Selenate), μg2 5 0
Table shows the composition of the tablet and powdered supplements. The iron sources for the supplements are ferrous fumarate in the tablet and 
micronized dispersible ferric pyrophosphate in the powdered supplement.BMC Pregnancy and Childbirth 2009, 9:33 http://www.biomedcentral.com/1471-2393/9/33
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Study Flow Diagram Figure 1
Study Flow Diagram.
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ing snack, consisting of oatmeal cookies, apple sauce and
juice, after the first blood draw. The morning snack con-
tained 1.5 mg of iron, 28.2 μg folic acid, and 88.0 mg of
ascorbic acid and no calcium or caffeine. Nutrient values
of the snack were determined either from product labels
or the Canadian Nutrient File [18]. Ascorbic acid was
incorporated into the standardized morning meal to
enhance iron bioavailability. A standardized low iron, low
folic acid lunch was consumed at the 4th hour of each,
assessment period. Subjects were encouraged to consume
all their food and the complete consumption of the pow-
dered supplement. The same food was consumed for all
three assessment periods. Changes in serum concentra-
tions of iron and folate were measured for each subject
during each of the two 8-hour assessment periods.
Assessment of Baseline Iron and Folate Status
Hemoglobin (Hb) concentration was measured prior to
insertion of the intravenous catheter to determine study
eligibility. Hb concentration was determined directly
from capillary blood via finger prick and measured using
a portable HEMOCUE B-Hb photometer (Hemocue,
Angelholm, Sweden) by the trained study coordinator
using standardized techniques. Initial blood samples on
the first assessment day were used to determine serum fer-
ritin concentration and serum transferrin receptor (sTfR)
for overall hematological status. Both ferritin and serum
transferrin receptor were measured using standard labora-
tory methods [19-21].
Serum Iron 'Area Under the Curve' (AUC)
Serum iron was measured using a colormetric assay (Vit-
ros Chemistry) with a quality control precision of 17.1 ±
0.35 μmol/L and CV of 3.1% [22,23]. Hemolyzed samples
were discarded. The changes in serum iron concentrations
over time were used to calculate the area under the plasma
curve (AUC0–8h) using the linear trapezoid rule [24]. Total
area under the curve for basal diurnal variation was meas-
ured from the concentrations of the serum iron during the
baseline assessment. Thus to account for the change in
serum iron due to diurnal variation, the baseline iron
measurements at each time point were subtracted from
those measured during assessment periods 2 and 3. The
adjusted area under the curve (for assessment periods 2
ands 3) was calculated as follows:
adjustedAUC[i,  j] = AUC[i,  j] - mean baseline AUC
[Adapted from Hoppe et al [25]]
Where i indicates participant and j indicates intervention
(powdered supplement or tablet) and the mean baseline
AUC for diurnal variation is the mean AUC value across
all subjects from the baseline visit as per Hoppe et al [25].
The individual baseline (diurnal variation) results were
also used to calculate the AUC; however this did not influ-
ence the statistical results. Relative bioavailability
(defined as the measure of bioavailability of the iron in
the powdered supplement against bioavailability of the
iron in the tablet {AUCa * dose b}/{AUCb * dose a} was
calculated.
Plasma Folate 'Area Under the Curve' (AUC)
As previously mentioned, since there is no discernable
diurnal variation for folate, plasma folate was not meas-
ured during the baseline assessment on the initial assess-
ment day [17]. Total folate concentration was assessed
using the microbiological assay as described by Molloy
and Scott [26] using Lactobacillus rhamnosus (ATCC 7649;
American Type Tissue Culture Collection, Manassas, VA)
as the test organism. All samples from the same subjects
were analyzed at the same time to reduce intra-subject var-
iability. A whole blood folate standard prepared by the
National Institutes for Biological Standards and Control
(NIBSC code 95/528, certified content of 29.51 nmol/L
(13 ng/ml), NIBSC Hertfordshire EN6 3QG United King-
dom) was used to assess the accuracy and precision of the
folate bioassay (a plasma folate certified standard does
not exist). The overall inter-assay coefficient of variation
for the whole blood folate standard was 9.1% with a mean
value of 32.2 ± 2.9 nmol/L (14.2 ± 1.3 ng/ml). Incremen-
tal AUC was measured during each assessment period for
each subject. Changes in plasma folate concentration at
each time period were calculated by subtracting the base-
line (the 08:00 AM value) from the subsequent values.
Statistics
A sample size calculation estimated that 16 women were
required to detect a statistically significant difference of 36
in AUC between the two groups (80% power and SD of
46). The estimated mean and SD for AUC were based on
previous literature [25]. A similar calculation was done for
folate which projected a sample size of 18 subjects to
detect a 20% difference in mean folate AUC with an α =
0.05 and 80% power [27]. To account for uncertainty
imposed by pregnancy and blood sampling, a 20% allow-
ance was added to the estimated sample size, thus 19
women were originally planned for recruitment. All data
collection sheets and lab reports were manually checked
for completeness and accuracy of data. Results from one
subject was excluded since iron concentration values from
the tablet supplement were greater than three standard
deviations above the overall distribution mean (p > 0.05).
A parametric analysis was performed with a repeated
measures analysis of variance model and Satterthwaite
formula to estimate degrees of freedom. The fixed effects
in the model were: age, gestational age, ferritin and parity.
Subject was included as the repeated effect. The pair-wise
differences of least squares means of the interventions
were tested using Tukey-Kramer p value adjustments. All
statistical tests were 2-tailed and a p-value of ≤ 0.05 wasBMC Pregnancy and Childbirth 2009, 9:33 http://www.biomedcentral.com/1471-2393/9/33
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considered statistically significant. Statistical software SAS
(version 9.1, SAS Institute Inc. Cary, North Carolina) was
used for the analysis.
Results
Results for hematologic and folate status are shown in
Table 2. Seventy-Two percent of plasma folate values were
above the normal range at baseline, while 50% of ferritin
values were below reference normal values for pregnant
women. Normality of variables was tested and found to
be not significant for Kolmogorov-Smirnov test with the
exception of ferritin. Ferritin was log transformed prior to
analysis.
AUC Measures for Iron
For each subject, baseline serum iron values did not signif-
icantly differ within subjects or between groups for all
three assessment periods. Values for basal diurnal varia-
tion AUC, adjusted AUC, peak concentration and time to
peak by treatment are shown in Table 3. Time to peak and
peak concentration were computed via the software pro-
gram (GraphPad Prism, version 4.0 2003, GraphPad Soft-
ware Inc, La Jolla, CA). Net changes in mean serum iron
concentrations are shown in Figure 2. There was a statisti-
cally significant difference in the change in serum iron
between supplements at 3- (p = 0.026), 4- (p = 0.0083)
and 8-hours (p = 0.0071) post ingestion. The AUC -iron
was significantly smaller for the powdered supplement
than for the tablet (p = 0.0003). Relative bioavailability
for micronized dispersible FePP in powdered supplement
was 22% compared to the ferrous fumarate in tablet sup-
plement.
AUC Measure for Folate
Baseline (8 am sample) mean plasma folate concentra-
tions did not differ within or between subjects. Values for
folate by intervention are shown in Table 3. AUC for
folate was not related to any of the other study variables
(Ferritin concentration, age, gestational age). Net changes
in mean plasma folate concentrations are shown in Figure
3. No significant differences were observed (p = 0.61) in
the area under the folate curve in the traditional tablet
supplement and in the new powdered supplement. There
was no difference in the peak absorption of either supple-
ment.
Discussion
Given the documented importance of vitamin and min-
eral supplementation during pregnancy and the relatively
poor adherence to currently available supplements, our
goal was to develop a supplement that was efficacious in
terms of iron and folic acid bioavailability, yet could
potentially result in improved adherence. Thus, we inves-
tigated the absorption kinetics of a micronized dispersible
form of ferric pyrophosphate (MDFP) with an emulsifier
coating and folic acid in a powdered multivitamin supple-
ment in healthy pregnant women versus ferrous fumarate
(non-encapsulated) in a traditional tablet supplement.
Both iron and folic acid were absorbed from the pow-
dered supplement, however based on the differences in
the area under the curve (AUC) and doses, the relative
bioavailability of iron from powdered supplement was
lower than from the tablet supplement (0.22), while folic
acid was greater (1.8).
In children, powdered supplements which included
encapsulated ferrous fumarate as the iron source were
shown to be equally as effective as ferrous sulfate drops at
reducing the incidence of iron deficiency anemia but with
improved adherence [10-14]. Using stable isotopes, it was
directly demonstrated that 8.3% of the encapsulated fer-
rous fumarate was absorbed in iron-deficient anemic chil-
dren compared to 4.3% in iron deficient and iron
sufficient children [28]. The MDFP in the powdered sup-
plement in the present study had a distinctly different
absorption curve from the ferrous fumarate in the tablet
supplement. It is possible that the emulsifier coating on
the MDFP delayed or reduced absorption of the iron by
keeping the iron suspended within the gastric lumen for a
longer period of time compared to the iron in the tablet
thereby increasing its interaction with dietary inhibitors
or allowing the MDFP to exit the stomach and duodenum
without being dissolved [29]. Other factors may also have
influenced the bioavailability of the iron in the powdered
Table 2: Baseline measures of iron and folate status under fasting conditions
Mean ± SD
N = 18
Range % outside normal range Direction
Hemoglobin g/dL 12.6 ± 0.8 10.6–13.7 0*
Serum Ferritin μg/L 14.1 ± 8.3 4.5–31.4 50** below
sTfR mg/L 3.2 ± 0.9 1.9–5.5 5.5*** above
Serum Iron μmol/L 14.0 ± 5.7 6.7–25.5 0****
Plasma folate nmol/L 57.2 ± 19.2 17.6–102.2 72***** above
n = 18. sTfR, serum transferrin receptor. *Hb cutoff during 2nd trimester is defined as 105 g/L and 110 g/L during third trimester[44] **Low ferritin 
values defined as <12 μg/L [43]. ***High sTfR values defined as 4.9 mg/L as per kit [21]. Serum iron for non-pregnant women is defined as 6.7–30.4 
μmol/L[23] **** High serum folate values defined as >45.3 nmol/L [41].BMC Pregnancy and Childbirth 2009, 9:33 http://www.biomedcentral.com/1471-2393/9/33
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Table 3: Area under the curve, basal diurnal variation (DV), serum iron and plasma folate by treatment
Basal Diurnal Variation (DV) Powdered Supplement Tablet Supplement
Iron
AUC (μmol·h/L) 104.5 ± 34.1
Adjusted AUC(after DV) (μmol·h/L) 10.0 ± 43.3* 41.8 ± 45.9*
Peak value (μmol/L) 14.6 3.0 8.9
Time to peak value (hrs) 34
Folate
Incremental AUC (nmol·h/L) NA 271.8 ± 110.9 248.7 ± 140.2
Peak value (nmol/L) NA 54.4 53.1
Time to peak value (hrs) NA 4 3
AUC, area under the curve. All values are mean ± SD; n(iron) = 17; n(folate) = 18 (sample size differed according to subject exclusion for iron 
variables). *p = 0.0003.
Mean incremental changes in serum iron concentrations between tablet and powdered supplements Figure 2
Mean incremental changes in serum iron concentrations between tablet and powdered supplements. Mean (± 
SEM) incremental changes in serum iron concentration in pregnant subjects over 8 hours after administration of either 27 mg 
of iron from ferrous fumarate in a traditional tablet supplement or 30 mg of iron from micronized dispersible ferric pyrophos-
phate in powdered supplement sprinkled over a standard meal. n = 17. The curve was adjusted for basal (diurnal) variation and 
the iron content of the standardized meal. There was a significant difference (p = 0.0003) between the relative bioavailability 
(as measured using AUC) of the iron in tablet supplement (41.8 ± 45.9 μmol·h/L) when compared to the iron in the powdered 
supplement (10.0 ± 43.3 μmol·h/L). The data were analyzed with the use of mixed-model repeated-measures with age, gesta-
tional age, ferritin concentration and parity as fixed effects and subject as the repeated effect. The pair-wise differences of least-
square means of the treatments were tested with the use of Tukey-Kramer p value adjustments.
0 1 2 3 4 5 6 7 8 9
0
2
4
6
8
10 Powdered Supplement
Tablet Supplement
Time (hours)
C
h
a
n
g
e
 
i
n
 
s
e
r
u
m
 
i
r
o
n
m
o
l
/
LBMC Pregnancy and Childbirth 2009, 9:33 http://www.biomedcentral.com/1471-2393/9/33
Page 8 of 11
(page number not for citation purposes)
supplement. Navarro et al [27,30] showed distinctly dif-
ferent curves in the absorption kinetics of iron in the com-
parison of a whole versus crushed tablet with the crushed
tablet having a lower absorption than the whole tablet. It
is possible that the smaller particle size in the crushed
form may enhance micronutrient interactions resulting in
reduced absorption of the iron, whereas the tablet form
may offer some protection from dietary inhibitors. Alter-
natively, the combination of powder form and emulsifier
coating could delay both the reduction of a portion of the
ferric form of iron to the ferrous form by dietary acids as
well as the transport of the ferric iron into the enterocyte
by the Integrin-Mobilferrin pathway [29].
Ferric pyrophosphate is significantly less bioavailable
than more water-soluble iron compounds, however
decreasing the particle size of the ferric pyrophosphate has
been shown to improve its bioavailability [16]. It has been
suggested that the relative bioavailability of MDFP may be
more influenced by the food matrix and other dietary
inhibitors than more soluble forms of iron [16,29]. Hall-
berg et al [31] found that the relative bioavailability of ele-
mental iron powders could be markedly affected
depending on the food matrix within which they were
studied possibly due to different rates of dissolution with
different meals. In the current study, it is likely that the
food matrix had a more significant effect on the gastric
dissolution of the SunActive Fe in the powdered supple-
ment than it did on the ferrous fumarate in the tablet.
Ascorbic acid acts as both a reducer and a chelator in the
intestinal lumen to promote iron absorption. Previous
studies have found that addition of ascorbic acid had less
of a promoting effect on the absorption of ferric pyro-
phosphate than it did on ferrous sulfate, decreasing the
relative bioavailability of ferric pyrophosphate [29,32]. In
the present study, both the tablet and the powdered sup-
plement contained ascorbic acid (100 vs 70 mg respec-
tively) and an additional 88 mg was consumed at
breakfast when the supplements were taken. It is possible
that the addition of ascorbic acid from both the supple-
ment and the food matrix promoted the absorption of the
ferrous fumarate in the tablet supplement more than it
Mean incremental changes in plasma folate concentrations between tablet and powdered supplements Figure 3
Mean incremental changes in plasma folate concentrations between tablet and powdered supplements. Mean 
(± SEM) changes in plasma folate concentrations in pregnant subjects over 8 hours after administration of either 1000 μg folic 
acid in the traditional tablet supplement or 600 μg folic acid in the powdered supplement sprinkled over a standard meal. n = 
18. There was no significant difference in the area under the folate absorption curve in the tablet supplement (248.7 ± 140.2 
nmol·h/L) when compared to the folic acid in the powdered supplement (271.8 ± 110.9 nmol·h/L). The data were analyzed with 
the use of mixed-model repeated measures with age, gestational age, ferritin concentration and parity as fixed effects and sub-
ject as the repeated effect. The pair-wise differences of least-square means of the treatments were tested with the use of 
Tukey-Kramer P value adjustments.
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promoted the absorption of the MDFP in the powder sup-
plement. Calcium and zinc (at high doses) have been
noted to depress iron absorption [33,34]. Despite the fact
that the powdered supplement contained no calcium and
a low dose of zinc, iron absorption was not enhanced. We
assume that the impact of the food matrix had the strong-
est impact on iron absorption.
Given the lower relative bioavailability of the iron in pow-
der supplement, MDFP may not be the best iron source
for the powder supplement. MDFP was chosen because it
causes less organoleptic changes to foods than ferrous
fumarate and it is dispersible in liquids due to its emulsi-
fier coating. Initial studies using erythrocyte incorpora-
tion methodology demonstrated that it was as well
absorbed as ferrous sulfate [16]. In addition, we recently
reported significant and similar increases in hemoglobin
and ferritin concentrations among children randomized
to either powdered ferrous fumarate or MDFP at varying
doses compared to ferrous glycine sulfate drops after an
eight 8 week intervention [35]. This study however, did
not attempt to measure the impact on iron status of the
different iron compounds.
The relative bioavailability of the folic acid was greater in
the powdered form than the tablets despite the higher
dosage in the tablet (1000 vs. 600 μg). This observation
supports earlier evidence that the absorption of folic acid
may be blunted at high oral intake. The relative response
of folic acid seems to be more effective at lower doses and
absorption curves have been shown to plateau at higher
doses [36]. Doses of folic acid above 200 μg have resulted
in the appearance of unmetabolized folic acid in serum
[37]. Houghton et al [38] found no evidence of further
RBC folate increase above an oral intake of 475 μg while
Caudill et al [39] found no difference in RBC folate
between 450 and 850 μg of folate per day. Wright et al
[40] found that folic acid does not appear to be reduced
in the intestine as previously thought but rather appears to
enter the hepatic portal vein unaltered and is sequestered
and metabolized in the liver. Since the liver has a limited
capacity to convert folic acid to dihydrofolate, a form uti-
lized by the body, significant amounts of folic acid can
enter circulation [40]. Wright also showed that the plasma
response to a folate containing meal included endog-
enous folate as well as the folate in the meal. [40]. How-
ever, we demonstrated no difference in relative
bioavailability despite the difference in doses. In the cur-
rent study, mean plasma folate from the entire cohort was
above the reference normal range [41]. These elevated lev-
els suggest that the folic acid intake from both supple-
ments exceeds the metabolic capacity of the liver cells and
would likely contribute to the presence of unmetabolized
folic acid in maternal serum (although this was not meas-
ured in the current study). These high intakes could be
exposing developing fetuses to undesirable levels of
unmetabolized folic acid for which the long-term conse-
quences are unknown [42]. The results of the current
study support the current WHO recommendation of
including no more than 400 μg of folic acid in prenatal
supplements, particularly in countries that mandate folate
fortification [43].
This study only measured relative bioavailability, there-
fore it was not possible to determine how much of the
micronized dispersible ferric pyrophosphate was
absorbed and whether it would be sufficient to maintain
iron status during pregnancy. Further investigation is
needed to determine whether this form of iron is effective
at maintaining iron status during pregnancy. Although
not anticipated, about half of the subjects were iron
depleted at baseline even though hemoglobin was within
normal range for pregnancy[44]. Thus extrapolation of
the results to an iron-replete population may not be
appropriate. It is suggested in the literature that low iron
stores should have actually increased the absorption of
the iron from the supplements rather than decreasing
it[45]. However, we showed no correlation between the
AUC for serum iron and ferritin likely due to the small
sample size of the study. Similarly, this study was not
designed to examine the adherence of a powdered min-
eral supplement versus traditional tablets, nor the efficacy
of one versus the other. Both the iron and folic acid were
absorbed from the powdered supplement, although the
iron in the powdered supplement was significantly less
bioavailable than the iron in the tablet supplement and
folate was more bioavailable from the lower-dose powder
supplement. While our ability to extrapolate the relative
bioavailability of the iron was impeded by the curve not
approaching baseline, it is evident that the iron in the
powdered supplement did not perform as expected. Fur-
ther clinical studies would need to be conducted to deter-
mine both the efficacy and effectiveness of the new
powdered supplement in pregnant women.
Conclusion
The lower bioavailability of the iron in the powdered sup-
plement was unexpected and contrary to previously pub-
lished reports. Since pills and capsules are known to be
poorly accepted by some women during pregnancy, espe-
cially those with significant morning sickness, we believe
it is reasonable to continue to look for alternative delivery
systems and forms of iron for this purpose.
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